OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
Nonhlanhla N. Mkhize, Anna Yssel, Haajira Kaldine, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 6, pp. e1011469-e1011469
Open Access | Times Cited: 23
Nonhlanhla N. Mkhize, Anna Yssel, Haajira Kaldine, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 6, pp. e1011469-e1011469
Open Access | Times Cited: 23
Showing 23 citing articles:
Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development
Maria C. Hesselman, Marius Zeeb, Peter Rusert, et al.
Cell Host & Microbe (2025)
Open Access | Times Cited: 1
Maria C. Hesselman, Marius Zeeb, Peter Rusert, et al.
Cell Host & Microbe (2025)
Open Access | Times Cited: 1
Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies
Jyoti Sutar, Priyanka Jayal, Ranajoy Mullick, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Jyoti Sutar, Priyanka Jayal, Ranajoy Mullick, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Current methods for detecting and assessing HIV-1 antibody resistance
Stanley Odidika, Martin Pirkl, Thomas Lengauer, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Stanley Odidika, Martin Pirkl, Thomas Lengauer, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes
Harry B. Gristick, Harald Hartweger, Yoshiaki Nishimura, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Harry B. Gristick, Harald Hartweger, Yoshiaki Nishimura, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance
Paula Marantz Cohen, Bronwen E. Lambson, Nonhlanhla N. Mkhize, et al.
Journal of Virology (2025)
Open Access
Paula Marantz Cohen, Bronwen E. Lambson, Nonhlanhla N. Mkhize, et al.
Journal of Virology (2025)
Open Access
A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses
Xiaoying Shen, Bette Korber, Rachel L. Spreng, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 133-133
Open Access
Xiaoying Shen, Bette Korber, Rachel L. Spreng, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 133-133
Open Access
Mechanisms, therapeutic strategies, and emerging therapeutic alternatives for carbapenem resistance in Gram-negative bacteria
Fatima Mourabiti, Fatimazahra Jouga, Souraya Sakoui, et al.
Archives of Microbiology (2025) Vol. 207, Iss. 3
Closed Access
Fatima Mourabiti, Fatimazahra Jouga, Souraya Sakoui, et al.
Archives of Microbiology (2025) Vol. 207, Iss. 3
Closed Access
HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges
Tamara Elliott, Daniel Bradshaw, Sarah Fidler
Current Opinion in HIV and AIDS (2025)
Closed Access
Tamara Elliott, Daniel Bradshaw, Sarah Fidler
Current Opinion in HIV and AIDS (2025)
Closed Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro Dianah Chawana, Stephen R. Walsh, Lynda Stranix‐Chibanda, et al.
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access
Tariro Dianah Chawana, Stephen R. Walsh, Lynda Stranix‐Chibanda, et al.
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses
Syamala Rani Thimmiraju, Jason T. Kimata, Jeroen Pollet
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 174-185
Open Access | Times Cited: 4
Syamala Rani Thimmiraju, Jason T. Kimata, Jeroen Pollet
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 174-185
Open Access | Times Cited: 4
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Sharana Mahomed
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 4
Sharana Mahomed
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 4
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Jianliang Xu, Tongqing Zhou, Krisha McKee, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 3
Jianliang Xu, Tongqing Zhou, Krisha McKee, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 3
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
Stephen R. Walsh, Cynthia L. Gay, Shelly Karuna, et al.
PLoS Medicine (2024) Vol. 21, Iss. 6, pp. e1004329-e1004329
Open Access | Times Cited: 3
Stephen R. Walsh, Cynthia L. Gay, Shelly Karuna, et al.
PLoS Medicine (2024) Vol. 21, Iss. 6, pp. e1004329-e1004329
Open Access | Times Cited: 3
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies
William O. Hahn, K. Rachael Parks, Mingchao Shen, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 10
Closed Access | Times Cited: 2
William O. Hahn, K. Rachael Parks, Mingchao Shen, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 10
Closed Access | Times Cited: 2
Anticipating HIV viral escape – resistance to active and passive immunization
Carolyn Williamson, Rebecca M. Lynch, Penny L. Moore
Current Opinion in HIV and AIDS (2023) Vol. 18, Iss. 6, pp. 342-348
Closed Access | Times Cited: 5
Carolyn Williamson, Rebecca M. Lynch, Penny L. Moore
Current Opinion in HIV and AIDS (2023) Vol. 18, Iss. 6, pp. 342-348
Closed Access | Times Cited: 5
Advancing bnAb combinations for HIV prevention
Henning Gruell, Philipp Schommers
The Lancet HIV (2023) Vol. 10, Iss. 10, pp. e625-e626
Closed Access | Times Cited: 5
Henning Gruell, Philipp Schommers
The Lancet HIV (2023) Vol. 10, Iss. 10, pp. e625-e626
Closed Access | Times Cited: 5
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B. Reeves, Bryan T. Mayer, Allan C. deCamp, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Daniel B. Reeves, Bryan T. Mayer, Allan C. deCamp, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 5
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies
William O. Hahn, K. Rachael Parks, Mingchao Shen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
William O. Hahn, K. Rachael Parks, Mingchao Shen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env–ferritin nanoparticle designs
Zekun Mu, Jill Whitley, Diana Martik, et al.
Journal of Virology (2024) Vol. 98, Iss. 9
Closed Access | Times Cited: 1
Zekun Mu, Jill Whitley, Diana Martik, et al.
Journal of Virology (2024) Vol. 98, Iss. 9
Closed Access | Times Cited: 1
Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study
Christopher Alba, Shelly Malhotra, S. Horsfall, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Christopher Alba, Shelly Malhotra, S. Horsfall, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development
Maria C. Hesselman, Marius Zeeb, Peter Rusert, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Maria C. Hesselman, Marius Zeeb, Peter Rusert, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Generation of a Nonbilayer Lipid Nanoenvironment after Epitope Binding Potentiates Neutralizing HIV-1 MPER Antibody
Sara Insausti, Ander Ramos-Caballero, Brian Wiley, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 44, pp. 59934-59948
Open Access
Sara Insausti, Ander Ramos-Caballero, Brian Wiley, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 44, pp. 59934-59948
Open Access
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B. Hurt, Kathryn E. Stephenson, et al.
The Lancet HIV (2024) Vol. 12, Iss. 1, pp. e13-e25
Closed Access
Srilatha Edupuganti, Christopher B. Hurt, Kathryn E. Stephenson, et al.
The Lancet HIV (2024) Vol. 12, Iss. 1, pp. e13-e25
Closed Access
